Core Insights - Neuronetics reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.08, marking an earnings surprise of -87.50% [1] - The company generated revenues of $38.11 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 3.87% and significantly up from $16.45 million a year ago [2] - Neuronetics shares have increased approximately 189.4% year-to-date, outperforming the S&P 500's gain of 7.6% [3] Financial Performance - Over the last four quarters, Neuronetics has consistently failed to meet consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $39.04 million, and for the current fiscal year, it is -$0.37 on revenues of $150.72 million [7] Industry Context - Neuronetics operates within the Medical - Instruments industry, which is currently ranked in the bottom 37% of over 250 Zacks industries [8] - The performance of Neuronetics' stock may be influenced by the overall outlook of the industry, as top-ranked industries tend to outperform lower-ranked ones by a factor of more than 2 to 1 [8]